Mendus presenterar positiva överlevnadsdata från fas 2-studien ADVANCE II som utvärderar vididencel som underhållsbehandling vid AML vid ASH-konferensen
11 déc. 2023 13h30 HE
|
Mendus AB
Pressmeddelande Stockholm, 11 december 2023 Per den 24 november 2023 var återfallsfri medianöverlevnad (mRFS) 30,4 månader Medianen för totalöverlevnad (mOS) hade inte ännu inte uppnåtts, med...
Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023
11 déc. 2023 13h30 HE
|
Mendus AB
Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival (mRFS) stood at 30.4 months Median overall survival (mOS) was not reached, with the...
Q-Centrix Launches the Research Network to Expand the Impact of Clinical Data by Connecting Hospitals and Life Sciences Organizations
14 nov. 2023 08h00 HE
|
Q-Centrix
The platform builds upon Q-Centrix’s ethos that data management is critical to expanding clinical research and trials
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
03 nov. 2023 14h00 HE
|
ImCheck Therapeutics SAS
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...
Odesso Health’s Clinical Data Connector Launches On the athenahealth Marketplace and Appian AI Marketplace
02 nov. 2023 08h00 HE
|
Odesso Health
Odesso Health’s newest solution Clinical Data Connector, uses AI and machine learning to extract clinical data to automate EMR/EHR workflows and protect healthcare providers in electronic medical...
Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy
19 oct. 2023 08h00 HE
|
Neurona Therapeutics
First cohort treated in Ph I/II clinical trial of NRTX-1001 in adults with focal epilepsy, update on first patients'progress
Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting
16 oct. 2023 08h00 HE
|
Entera Bio Ltd.
JERUSALEM, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, presented...
H1 Launches H1 Mobile App to Empower Medical Affairs with Real-Time KOL Insights and Expertise on the Go
14 août 2023 09h00 HE
|
H1
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- H1, the leading source of truth for global HCP, clinical, scientific, and research information, today announced the release of the iOS mobile app, H1...
Monopar Provides Encouraging Camsirubicin Clinical Data Update
08 août 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for...
New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias
19 mai 2023 07h30 HE
|
BioSig Technologies, Inc.
Data from three abstracts highlight the potential of an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI) Preservation of raw unipolar signal using BioSig’s...